Haleon plc (NYSE:HLN) Stake Lowered by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC cut its holdings in Haleon plc (NYSE:HLN - Free Report) by 0.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 8,462,284 shares of the company's stock after selling 71,484 shares during the period. Haleon accounts for about 1.2% of Douglas Lane & Associates LLC's holdings, making the stock its 26th biggest position. Douglas Lane & Associates LLC owned 0.19% of Haleon worth $89,531,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. AE Wealth Management LLC increased its position in Haleon by 6.1% during the second quarter. AE Wealth Management LLC now owns 19,199 shares of the company's stock worth $159,000 after purchasing an additional 1,098 shares during the last quarter. Cardinal Capital Management raised its holdings in shares of Haleon by 2.5% in the 2nd quarter. Cardinal Capital Management now owns 46,231 shares of the company's stock worth $382,000 after purchasing an additional 1,140 shares during the period. Endowment Wealth Management Inc. lifted its position in Haleon by 9.9% during the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company's stock valued at $106,000 after buying an additional 1,161 shares in the last quarter. Portside Wealth Group LLC lifted its holdings in shares of Haleon by 2.7% during the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company's stock valued at $372,000 after acquiring an additional 1,182 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its holdings in Haleon by 18.5% in the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company's stock worth $84,000 after acquiring an additional 1,238 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

NYSE HLN traded down $0.07 during trading hours on Friday, hitting $10.05. The company had a trading volume of 3,079,115 shares, compared to its average volume of 5,128,434. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.80. The firm has a market cap of $45.80 billion, a P/E ratio of 33.50, a price-to-earnings-growth ratio of 2.93 and a beta of 0.26. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $10.17 and a 200-day simple moving average of $9.09.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $3.50 billion during the quarter, compared to the consensus estimate of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same quarter last year, the company posted $0.08 EPS. Equities analysts predict that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were paid a dividend of $0.0514 per share. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon's dividend payout ratio is presently 36.67%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HLN shares. Morgan Stanley raised their target price on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research note on Friday, September 20th. UBS Group raised shares of Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. The Goldman Sachs Group downgraded Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. Finally, Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Haleon presently has an average rating of "Buy" and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.